Cargando…

Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset

Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanternier, Fanny, Cohen-Akenine, Annick, Palmerini, Fabienne, Feger, Frédéric, Yang, Ying, Zermati, Yael, Barète, Stéphane, Sans, Beatrix, Baude, Cédric, Ghez, David, Suarez, Felipe, Delarue, Richard, Casassus, Philippe, Bodemer, Christine, Catteau, Adeline, Soppelsa, Frédérique, Hanssens, Katia, Arock, Michel, Sobol, Hagay, Fraitag, Sylvie, Canioni, Danièle, Moussy, Alain, Launay, Jean Marie, Dubreuil, Patrice, Hermine, Olivier, Lortholary, Olivier
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292130/
https://www.ncbi.nlm.nih.gov/pubmed/18404201
http://dx.doi.org/10.1371/journal.pone.0001906
Descripción
Sumario:Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease started during childhood (Group 1, n = 28) with those of patients whose disease started at adult's age (Group 2, n = 114). Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42% and 77% of patients in groups 1 and 2, respectively (p<0.001). 816 c-kit mutation was associated with systemic mastocytosis in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p = 0.0001). Other c-kit activating mutations were found in 23% of patients with mastocytosis' onset before the age of 5, 0% between 6 and 15 years and 2% at adults' age (p<0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the age of disease's onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy.